2024
Erratum to “An update on clinical presentation and responses to therapy of patients with hereditary hypophosphatemic rickets with hypercalciuria (HHRH).” Kidney International 2023;105:1058–1076
Zhu Z, Bo-Ran Ho B, Chen A, Amrhein J, Apetrei A, Carpenter T, Lazaretti-Castro M, Colazo J, McCrystal Dahir K, Geßner M, Gurevich E, Heier C, Simmons J, Hunley T, Hoppe B, Jacobsen C, Kouri A, Ma N, Majumdar S, Molin A, Nokoff N, Ott S, Peña H, Santos F, Tebben P, Topor L, Deng Y, Bergwitz C. Erratum to “An update on clinical presentation and responses to therapy of patients with hereditary hypophosphatemic rickets with hypercalciuria (HHRH).” Kidney International 2023;105:1058–1076. Kidney International 2024, 106: 159. PMID: 38906648, DOI: 10.1016/j.kint.2024.05.005.Peer-Reviewed Original ResearchBoth enantiomers of β-aminoisobutyric acid BAIBA regulate Fgf23 via MRGPRD receptor by activating distinct signaling pathways in osteocytes
Sakamoto E, Kitase Y, Fitt A, Zhu Z, Awad K, Brotto M, White K, Welc S, Bergwitz C, Bonewald L. Both enantiomers of β-aminoisobutyric acid BAIBA regulate Fgf23 via MRGPRD receptor by activating distinct signaling pathways in osteocytes. Cell Reports 2024, 43: 114397. PMID: 38935499, DOI: 10.1016/j.celrep.2024.114397.Peer-Reviewed Original ResearchActivate distinct signaling pathwaysSignaling pathwayFibroblast growth factor 23Urinary phosphate excretionReceptor type DInduce FGF23Urine phosphateElevated FGF23Phosphate excretionFGF23L-BAIBAExercise-induced increasePhosphate homeostasisSclerostinPhosphate metabolismReceptorsD-enantiomerBonePathwayAn update on clinical presentation and responses to therapy of patients with hereditary hypophosphatemic rickets with hypercalciuria (HHRH)
Zhu Z, Bo-Ran Ho B, Chen A, Amrhein J, Apetrei A, Carpenter T, Lazaretti-Castro M, Colazo J, McCrystal Dahir K, Geßner M, Gurevich E, Heier C, Simmons J, Hunley T, Hoppe B, Jacobsen C, Kouri A, Ma N, Majumdar S, Molin A, Nokoff N, Ott S, Peña H, Santos F, Tebben P, Topor L, Deng Y, Bergwitz C. An update on clinical presentation and responses to therapy of patients with hereditary hypophosphatemic rickets with hypercalciuria (HHRH). Kidney International 2024, 105: 1058-1076. PMID: 38364990, PMCID: PMC11106756, DOI: 10.1016/j.kint.2024.01.031.Peer-Reviewed Original ResearchResponse to therapyHereditary hypophosphatemic ricketsPathogenic variantsBone phenotypeSerum phosphateHypophosphatemic ricketsHeterozygous carriersPartial response to therapyPredicting response to therapyRare group of disordersIntact parathyroid hormoneUrine calcium excretionCorrection of hypophosphatemiaSolute carrier familyDecreased serum phosphateBaseline disease severityVariants in vitroOral phosphate supplementationNormalize serum phosphateStandard of careGroup of disordersMutant allelesCarrier familyBiochemical phenotypeKidney phenotypeTumor-induced Osteomalacia, Treatment
Bergwitz, C Clinical Keys Tumor-induced Osteomalacia, Treatment, Elsevier, 2024, https://www.elsevier.com/products/clinicalkeyPeer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
2023
Hereditary Hypophosphatemic Rickets with Hypercalciuria Presenting with Enthesopathy, Renal Cysts, and High Serum c-Terminal FGF23: Single-Center Experience and Systematic Review
Dodamani M, Memon S, Karlekar M, Lila A, Khan M, Sarathi V, Arya S, Jamale T, Thakare S, Patil V, Shah N, Bergwitz C, Bandgar T. Hereditary Hypophosphatemic Rickets with Hypercalciuria Presenting with Enthesopathy, Renal Cysts, and High Serum c-Terminal FGF23: Single-Center Experience and Systematic Review. Calcified Tissue International 2023, 114: 137-146. PMID: 37981601, DOI: 10.1007/s00223-023-01156-2.Peer-Reviewed Original ResearchConceptsSingle-center experienceHereditary hypophosphatemic ricketsRenal calcificationSLC34A3 mutationsSystematic reviewHypophosphatemic ricketsLow bone mineral densityC-terminal FGF23Median age 38 yearsBone mineral densityIron deficiency anemiaPhenotype-genotype correlationAge 38 yearsDisorders of phosphate homeostasisRickets/osteomalaciaNon-truncating variantsLow BMDNormal BMDBone involvementDeficiency anemiaSingle-centerMineral densityCase seriesElevated FGF23Initial misdiagnosisMultifocal heterotopic ossification in a man with germline variants of LIM Mineralization Protein‐1 (LMP‐1)
Sangadala S, Shore E, Xu M, Bergwitz C, Lozano‐Calderon S, Lin A, Boden S, Kaplan F. Multifocal heterotopic ossification in a man with germline variants of LIM Mineralization Protein‐1 (LMP‐1). American Journal Of Medical Genetics Part A 2023, 191: 2164-2174. PMID: 37218523, DOI: 10.1002/ajmg.a.63304.Peer-Reviewed Original ResearchConceptsLIM mineralization protein-1Bone morphogenetic protein (BMP) pathwayGermline variantsBone morphogenetic proteinRecombinant BMP-2LMP-1Gene-disease relationshipsC2C12 cellsGenetic analysisIntracellular proteinsWT proteinHeterotopic ossificationProtein pathwayOsteoblast markersWT cellsBMP-2Protein 1Coding variantsGene-diseaseProtein levelsControl cellsPathogenic variantsLMP-1 variantsCo-transfectionMC3T3 cellsTumor-induced Osteomalacia, Diagnosis
Bergwitz, C Clinical Keys Tumor-induced Osteomalacia, Diagnosis, Elsevier, 2023, https://www.elsevier.com/products/clinicalkeyPeer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
2022
X-Linked Hypophosphatemic Rickets, Diagnosis
Bergwitz, C Clinical Keys X-Linked Hypophosphatemic Rickets, Diagnosis, Elsevier, 2022Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsX-Linked Hypophosphatemic Rickets, Treatment
Bergwitz, C Clinical Keys X-Linked Hypophosphatemic Rickets, Treatment, Elsevier, 2022, https://www.elsevier.com/products/clinicalkeyPeer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
2021
Phosphorus bioaccessibility measured in four amino acid–based formulas using in-vitro batch digestion translates well into phosphorus bioavailability in mice
Chande S, Dijk F, Fetene J, Yannicelli S, Carpenter TO, van Helvoort A, Bergwitz C. Phosphorus bioaccessibility measured in four amino acid–based formulas using in-vitro batch digestion translates well into phosphorus bioavailability in mice. Nutrition 2021, 89: 111291. PMID: 34111672, PMCID: PMC8588148, DOI: 10.1016/j.nut.2021.111291.Peer-Reviewed Original ResearchConceptsPhosphorus bioavailabilityAmino acid-based formulaProton pump inhibitorsDigestion modelBioavailability analysisPlasma phosphorus levelsLow phosphorus dietDigestion conditionsBioaccessibilityBioavailabilityStomach acidificationDigestive conditionsIntact fibroblast growth factor 23Phosphorus dietFibroblast growth factor 23Stomach pH.Intact parathyroid hormoneAcid-suppressive medicationsDihydroxy vitamin DGrowth factor 23Phosphorus levelsPhosphorus bioaccessibilityAcidificationPhosphorusIntact fibroblast growth factorFGF23 signalling and physiology.
Ho BB, Bergwitz C. FGF23 signalling and physiology. Journal Of Molecular Endocrinology 2021, 66: r23-r32. PMID: 33338030, PMCID: PMC8782161, DOI: 10.1530/jme-20-0178.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsO-glycosylation of FGF23FGF23 signalingSubtilisin-like proprotein convertase furinSuppressing phosphate reabsorptionProprotein convertase furinPost-translationallyO-glycosylationIntact FGF23C-terminusGenetic activityPrevent proteolysisParacrine FGFsHigh-affinity binding sitesFibroblast growth factor 23Fruit flyActive intact FGF23Convertase furinChronic kidney diseaseFGF23 fragmentsGrowth factor 23Physiological roleEndocrine FGFsDihydroxyvitamin D synthesisHyperphosphatemic disordersIntestinal phosphate absorptionNormal Physiology of Bone and Mineral Homeostasis
Bergwitz C, Wysolmerski J Normal Physiology of Bone and Mineral Homeostasis. Cecil Essentials of Medicine, 10th ed. 2021 ISBN978-0-323-72271-1, Chapter 74, pages 729-738Chapters
2020
Different elemental infant formulas show equivalent phosphorus and calcium bioavailability in healthy volunteers
Bergwitz C, Eussen SRBM, Janssens PLHR, Visser M, Carpenter TO, van Helvoort A. Different elemental infant formulas show equivalent phosphorus and calcium bioavailability in healthy volunteers. Nutrition Research 2020, 85: 71-83. PMID: 33450668, DOI: 10.1016/j.nutres.2020.11.004.Peer-Reviewed Original ResearchConceptsGeometric mean ratiosAcid-suppressive medicationsArea under the curveHealthy volunteersSerum phosphateCalcium bioavailabilityGastric acid-suppressive medicationsRetrospective chart reviewSerum calcium concentrationBioavailability of phosphorusCross-over studyInfant formulaElemental formula useSingle oral doseCalcium excretionDouble-blindGram of phosphorusSingle-centerChart reviewOral doseOvernight fastingSerum phosphorusBioequivalence criteriaWashout periodMean ratiosImportance of Dietary Phosphorus for Bone Metabolism and Healthy Aging
Serna J, Bergwitz C. Importance of Dietary Phosphorus for Bone Metabolism and Healthy Aging. Nutrients 2020, 12: 3001. PMID: 33007883, PMCID: PMC7599912, DOI: 10.3390/nu12103001.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsDietary phosphorusReduced bioavailabilityHealthy agingHigh dietary phosphorusSources of dietary phosphorusReduced longevityAbundance of phosphorusBone metabolismWestern dietPhosphorusTissue calcificationMetabolic changesEndocrine regulationBioavailabilityNormal amountsTissueCurrent knowledgeAbundanceDifferent tissuesExcessive lossOsteomalaciaTargeted FGFR Blockade for the Treatment of Tumor-Induced Osteomalacia
Hartley IR, Miller CB, Papadakis GZ, Bergwitz C, Del Rivero J, Blau JE, Florenzano P, Berglund JA, Tassone J, Roszko KL, Moran S, Gafni RI, Isaacs R, Collins MT. Targeted FGFR Blockade for the Treatment of Tumor-Induced Osteomalacia. New England Journal Of Medicine 2020, 383: 1387-1389. PMID: 32905668, PMCID: PMC7561341, DOI: 10.1056/nejmc2020399.Peer-Reviewed Original ResearchMeSH KeywordsAgedChondrosarcoma, MesenchymalDisease ProgressionFatal OutcomeFibroblast Growth Factor-23Fibroblast Growth FactorsHumansMaleMolecular Targeted TherapyNeoplasms, Connective TissueOsteomalaciaParaneoplastic SyndromesPhenylurea CompoundsPositron Emission Tomography Computed TomographyPyrimidinesReceptor Protein-Tyrosine KinasesReceptor, Fibroblast Growth Factor, Type 1Slc20a1/Pit1 and Slc20a2/Pit2 are essential for normal skeletal myofiber function and survival
Chande S, Caballero D, Ho BB, Fetene J, Serna J, Pesta D, Nasiri A, Jurczak M, Chavkin NW, Hernando N, Giachelli CM, Wagner CA, Zeiss C, Shulman GI, Bergwitz C. Slc20a1/Pit1 and Slc20a2/Pit2 are essential for normal skeletal myofiber function and survival. Scientific Reports 2020, 10: 3069. PMID: 32080237, PMCID: PMC7033257, DOI: 10.1038/s41598-020-59430-4.Peer-Reviewed Original ResearchConceptsHyp miceMuscle functionSkeletal muscleMyofiber functionNormal body weightSkeletal muscle atrophyGene dose-dependent reductionConditional knockout miceReduced oxygen consumption rateStimulation of AMP kinaseKnockout miceHypophosphatemic disordersMuscle atrophyERK1/2 activationGrip strengthConditional deletionHormonal changesLow bloodBody weightC2C12 myoblastsMiceFurther evaluationBlood phosphateDependent reductionAMP kinaseChapter 20 Phosphorus homeostasis and related disorders
Carpenter T, Bergwitz C, Insogna K. Chapter 20 Phosphorus homeostasis and related disorders. 2020, 469-507. DOI: 10.1016/b978-0-12-814841-9.00020-8.ChaptersEndocrine fibroblast growth factorsSupply of phosphateComplex regulatory systemMolecular regulationRegulatory signalsFibroblast growth factorIntricate mechanismsPhosphate transferRegulatory systemNovel targetBone biologyMammalian boneCritical roleDistinct classesGrowth factorSkeletal mineralizationCentral rolePhosphate metabolismPrincipal mediatorEndocrine organClasses of transportersPhosphorus homeostasisBiologyTransportersLocal milieuDescription of a novel SLC34A3.c.671delT mutation causing hereditary hypophosphatemic rickets with hypercalciuria in two adolescent boys and response to recombinant human growth hormone
Dreimane D, Chen A, Bergwitz C. Description of a novel SLC34A3.c.671delT mutation causing hereditary hypophosphatemic rickets with hypercalciuria in two adolescent boys and response to recombinant human growth hormone. Therapeutic Advances In Musculoskeletal Disease 2020, 12: 1759720x20912862. PMID: 32963591, PMCID: PMC7488884, DOI: 10.1177/1759720x20912862.Peer-Reviewed Original ResearchRecombinant human growth hormoneHereditary hypophosphatemic ricketsOral phosphate supplementationAffected brothersHuman growth hormoneHypophosphatemic ricketsResponse to rhGHBorn to unrelated parentsSequence analysisParameters of mineral homeostasisPhosphate supplementationRenal phosphate leakWhole-exome sequencing analysisGrowth hormone therapyGrowth hormoneBiochemical parameters of mineral homeostasisAccelerated linear growthImprove linear growthUrine biochemical parametersAutosomal recessive disorderRenal phosphate reabsorptionAffected brotherExome sequencing analysisWhole-exome sequencingSanger sequencing analysis
2019
Transgenic mouse model for conditional expression of influenza hemagglutinin-tagged human SLC20A1/PIT1
Chande S, Ho B, Fetene J, Bergwitz C. Transgenic mouse model for conditional expression of influenza hemagglutinin-tagged human SLC20A1/PIT1. PLOS ONE 2019, 14: e0223052. PMID: 31613887, PMCID: PMC6793878, DOI: 10.1371/journal.pone.0223052.Peer-Reviewed Original ResearchMeSH KeywordsActinsAnimalsBeta-GlobinsBiological TransportBone DensityCalcitriolChickensCytomegalovirusFemaleFibroblast Growth Factor-23Fibroblast Growth FactorsFounder EffectHemagglutinin Glycoproteins, Influenza VirusHumansMaleMiceMice, TransgenicOsteoblastsParathyroid HormonePhosphatesPrimary Cell CulturePromoter Regions, GeneticRabbitsRecombinant Fusion ProteinsSkullTranscription Factor Pit-1TransgenesConceptsPrimary calvaria osteoblastsLoxP-stop-loxPLoxP-STOP-loxP cassetteMouse modelDihydroxy vitamin D levelsHemagglutinin (HABone mineral densityVitamin D levelsInfluenza hemagglutinin (HAConditional mouse modelActivation of transgene expressionElevated plasma PiTransgenic mouse modelPlasma iPTHUrine PiBeta-globin geneSerum calciumWT littermatesMineral densityDays of ageProtein excretionD levelsSemi-quantitative RT-PCRStandard chowTransgenic miceEndocrine regulation of MFS2 by branchless controls phosphate excretion and stone formation in Drosophila renal tubules
Rose E, Lee D, Xiao E, Zhao W, Wee M, Cohen J, Bergwitz C. Endocrine regulation of MFS2 by branchless controls phosphate excretion and stone formation in Drosophila renal tubules. Scientific Reports 2019, 9: 8798. PMID: 31217461, PMCID: PMC6584732, DOI: 10.1038/s41598-019-45269-x.Peer-Reviewed Original ResearchConceptsDrosophila renal tubulesFly life spanGenetic ablationRNAi-mediated knockdownInorganic phosphate (Pi) homeostasisHigh-Pi mediumPi transportersAdult fliesControl of FGF signalingHigher speciesPi mediumInduces expressionMFS2FGF signalingExcretion of PiPhosphate homeostasisDrosophilaFly longevityEndocrine regulationHormone fibroblast growth factor 23Renal tubulesHormonal controlPi transportFibroblast growth factor 23Genetic overexpression